Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind trial of doravirine/islatravir vs bictegravir/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 infection
jRCT2031210024Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of doravirine and islatravir in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of participants with HIV-1 RNA <50 copies/mL at Week 48, Percentage of participants experiencing ≥1 adverse event (AE) and 1 more. Started May 2021; status: completed.
02
Drugs
doravirineislatravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on jRCT2031210024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210024.